PDF(Pubmed)
Abstract：
Stanozolol shows promise as an anabolic and anti-catabolic agent for treating degenerative joint disease (DJD). This study assessed the clinical efficacy of a single intra-articular stanozolol injection in canine knees with DJD and its correlation with serum IL-1β levels. Thirty dogs (n = 30) were divided into a control group (CG, n = 10) and a study group (SG, n = 20) with DJD. Pain levels were assessed using the Brown query, and radiographs were taken at T0 and T3. IL-1β levels were quantified via ELISA. Apart from 2 patients, all showed reduced pain intensity, with 15 patients showing improvement at T1 and 3 patients at T2. A positive correlation (r = 0.84; p < 0.01) was found between pain level and IL-1β in 15 patients. No systemic effects were observed. Most patients (18/20) experienced reduced pain. This pilot study suggests stanozolol\'s potential in managing DJD in dogs. Further research is warranted to validate these findings and understand stanozolol\'s mechanism in DJD treatment.
摘要：
Stanozolol显示出有望作为治疗退行性关节病（DJD）的合成代谢和抗分解代谢剂。本研究评估了单一关节腔内注射司坦唑醇在DJD犬膝关节中的临床疗效及其与血清IL-1β水平的相关性。30只狗（n=30）分为对照组（CG，n=10）和一个研究组（SG，n=20)与DJD。使用布朗查询评估疼痛水平，在T0和T3拍摄X线照片。通过ELISA定量IL-1β水平。除了2名患者，都显示疼痛强度降低，15名患者在T1和3名患者在T2时显示改善。15例患者的疼痛水平与IL-1β呈正相关(r=0.84;p<0.01)。没有观察到全身效应。大多数患者（18/20）经历疼痛减轻。这项初步研究表明，司坦唑醇在管理狗的DJD方面具有潜力。需要进一步的研究来验证这些发现并了解司坦唑醇在DJD治疗中的作用机制。
